Journal of Clinical Pharmacology

Clubley, M., Bye, C. E., Henson, T. A., Peck, A. W. and Riddington, C. J., Effects of caffeine and cyclizine alone and in combination on human performance, subjective effects and EEG activity. British Journal of Clinical Pharmacology 7 157-63, 1979. [Pg.291]

Hildebrand, M. and Seifert, W., Determination of acetylator phenotype in Caucasians with caffeine. Journal of Clinical Pharmacology 37, 525-526, 1981. [Pg.297]

Denaro, C. P., Brown, C. R., Jacob, P., Benowitz, N. L., Effects of caffeine with repeated dosing. European Journal of Clinical Pharmacology, 40, 273-278, 1991. [Pg.301]

Bruce, M., Scott, N., Lader, M. and Marks, V., The psychopharmacological and electrophysiological effects of a single dose of caffeine in healthy human subjects. British Journal of Clinical Pharmacology 22, 81-87, 1986. [Pg.303]

Zhou, M., Liu, P., Zhang, H. Y. et al. (2002). Double-blind comparison between risperidone and haloperidol in the treatment of schizophrenic patients. Chinese Journal of Clinical Pharmacology, 18(5), 341. ... [Pg.96]

DeAngelis, Catherine D. and Phil B. Fontanarosa, Conflicts over Conflicts of Interest , Journal of the American Medical Association (2009) http / /jama, ama-assn.org/misc/jed900i2pap Ei E3.pdf de Craen, Anton J. M., D. E. Moerman, S. H. Heisterkamp, G. N. J. Tytgat, J. G. Tijssen andj. Kleijnen, Placebo Effect in the Treatment of Duodenal Ulcer , British Journal of Clinical Pharmacology 48 (1999) 853-60... [Pg.199]

Campbell M, Young PI, Bateman DN, Smith JM and Thomas SHL (1999). The use of atypical antipsychotics in the management of schizophrenia. British Journal of Clinical Pharmacology, 4,1, 13-22. [Pg.260]

Carlini EA and Cunha JM (1981). Hypnotic and antiepileptic effects of cannabidiol. Journal of Clinical Pharmacology, 21(Suppl. 8-9), 417s-427s. [Pg.260]

Hindmarch I, Parrott AC and Lanza M (1979). The effects of ergot alkaloid derivative (Hydergine) on aspects of psychomotor performance, arousal, and cognitive processing ability. Journal of Clinical Pharmacology, 19, 726-732. [Pg.268]

Noyes R, Brunk SF, Baram DA and Canter AC (1975a). Analgesic effect of delta-9-tetrahy-drocannabinol. Journal of Clinical Pharmacology, 15, 139-143. [Pg.276]

Subhan Z and Hindmarch I (1987). Psychopharmacological effects of vinpocetine in normal healthy volunteers. European Journal of Clinical Pharmacology, 28, 567-571. [Pg.285]

Jefferys, D. and Jones, K. 1995. EMEA and the new pharmaceutical procedures for Europe. European Journal of Clinical Pharmacology 47, 471-476. [Pg.102]

Joshi, A., Bauer, R., Kuebler, P, White, M., Leddy, C., Compton, P., Garovoy, M., Kwon, P., Walicke, P., and Dedrick, R. 2006. An overview of the pharmacokinetics and pharmacodynamics of efalizumab a monoclonal antibody approved for use in psoriasis. Journal of Clinical Pharmacology 46(1), 10-20. [Pg.417]

De Ponti, F., Poluzzi, E. and Montanaro, N. (2000) QT-interval prolongation by non-cardiac drugs lessons to he learned from recent experience. European Journal of Clinical Pharmacology, 56, 1-18. [Pg.79]

Allen, M.J., Nichols, D.J. and Oliver, S.D. (2000) The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. British Journal of Clinical Pharmacology, 50, 247-253. [Pg.84]

Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. Journal of Clinical Pharmacology, 46, 498-507. [Pg.88]

N. (2001) Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs a call for consensus. European Journal of Clinical Pharmacology, 57, 185-209. [Pg.123]

Bertilsson, L., Carrillo, J.A., Dahl, M.L., Llerena, A., Aim, C., Bondesson, U., Lindstrom, L., Rodriguez dela Rubia, I., Ramos, S. and Benitez, J. (1994) Clozapine disposition covaries with CYP1A2 activity determined hy a caffeine test. British Journal of Clinical Pharmacology, 38 (5), 471 173. [Pg.232]

Nakajima, M., Kohayashi, K., Shimada, N., Tokudome, S., Yamamoto, T. and Kuroiwa, Y. (1998) Involvement of CYP1A2 in mexiletine metabolism. British Journal of Clinical Pharmacology, 46 (1), 55-62. [Pg.232]

Ha, H.R., Chen, J., Freiburghaus, A.U. and Follath, F. (1995) Metabolism of theophylline by cDNA-expressed human cytochromes P-450. British Journal of Clinical Pharmacology, 39 (3), 321-326. [Pg.232]

Balogh, A., Harder, S., Vollandt, R. and Staib, A.H. (1992) Intra-individual variability of caffeine elimination in healthy subjects. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 30 (10), 383—387. [Pg.233]

Bonnabry, P., Leemann, T. and Dayer, P. (1996) Role of human liver microsomal CYP2C9 in the biotransformation of lomoxicam European Journal of Clinical Pharmacology, 49 (4), 305—308. [Pg.234]

Kenworthy, K.E., Bloomer, J.C., Clarke, S.E. and Houston, J.B. (1999) CYP3A4 drug interactions correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology, 48 (5), 716-727. [Pg.237]

Ito, K., Brown, H.S. and Houston, J.B. (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. British Journal of Clinical Pharmacology, 57 (4), 473—486. [Pg.241]

Tarrus, E., Cami, J., Roberts, D.J., Spickett, R.G., Celdran, E. and Segura, J. (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. British Journal of Clinical Pharmacology, 23 (1), 9-18. [Pg.242]

Goldstein, J.A. (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology, 52, 349-355. [Pg.314]

Schwarz, U.I., Gramatte, T., Krappweis, J., Oertel, R. and Kirch, W. (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. International Journal of Clinical Pharmacology and Therapeutics, 38, 161-167. [Pg.363]

Drescher, S., Schaeffeler, E., Hitzl, M., Hofmann, U., Schwab, M., Brinkmann, U., Eichelbaum, M. and Fromm, M.F. (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. British Journal of Clinical Pharmacology, 53, 526-534. [Pg.364]

Rasmussen M.A. Colding-Jorgensen, M. Hansen, L.T. Bro, R. Multivariate evaluation of pharmacological responses in early clinical trials - A study of rIL-21 in the treatment of patients with metastatic melanoma. British Journal of Clinical Pharmacology, 2010, 69 (4), 379-390. [Pg.70]

Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I., Gawronska- and Szklarz, B. (2004) The MDRl 3435 polymorphism in patients with rheumatoid arthritis. International Journal of Clinical Pharmacology and Therapeutics. 42, 496-503. [Pg.432]

A very useful review of the history and development of the Declaration of Helsinki in the last four decades from its evolution from the principles enunciated in the Nuremberg Code of 1947 to the current version has been published in the British Journal of Clinical Pharmacology and is recommended reading, it includes the texts of the various versions of the Declaration. [Pg.722]

Lefevre, G., Pommier, F., Sedek, G., Allison, M., Huang, H.L., Kiese, B., Ho, Y.Y. and Appel-Dingemanse, S. (2008) Pharmacokinetics and bioavailahdity of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. Journal of Clinical Pharmacology, 48, 246—252. [Pg.67]

Smith, C.C., Bennett, P.M., Pearce, H.M., Harrison, P.I., Reynolds, D.J., Aronson, J.K. and Grahame-Smith, D.G. (1996) Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. British Journal of Clinical Pharmacology, 42, 423—429. [Pg.188]

Huang, S.M. and Lesko, L.J. (2004) Drug-drug, drug-dietary supplement, and drug-dtrus fmit and other food interactions what have we learned Journal of Clinical Pharmacology, 44, 559-569. [Pg.188]

Venkatakrishnan, K, Von Moltke, L.L. and Greenblatt, D.J. (2001) Human drug metabolism and the qrtochromes P450 application and relevance of in vitro models. Journal of Clinical Pharmacology, 41, 1149-1179. [Pg.195]

Rolan, P.E. (1994) Plasma protein binding displacement interactions-why are they still regarded as clinically important British Journal of Clinical Pharmacology,... [Pg.216]

Maher, B. and Back, D.J. (2001) Effect of al-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. British Journal of Clinical Pharmacology, 51, 99-102. [Pg.216]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...